You are here: Home » PTI Stories » National » News
Business Standard

Zydus Cadila gets USFDA nod to market anti-dementia tablets

Press Trust of India  |  New Delhi 

Zydus Cadila has received final approval from the US health regulator to market Memantine Hydrochloride tablets, used to treat dementia, in America, its listed entity said today.

"Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Memantine Hydrochloride tablets USP, 5mg and 10mg," said in a filing.

The company will manufacture the drug at its plant in Moraiya,

It has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

The stock was trading 0.07 per cent down at Rs 517.15 apiece on today.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, July 12 2017. 12:22 IST